New allelic arrangement CYP2D6*36x2 found in a Japanese poor metabolizer of debrisoquine

被引：19
作者：
Chida, M
Ariyoshi, N
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构：
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam, Sapporo, Hokkaido, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
[4] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
来源：
PHARMACOGENETICS | 2002年 / 12卷 / 08期
关键词：
CYP2D6*10; gene duplication; genotype;
D O I：
10.1097/00008571-200211000-00011
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：659 / 662
页数：4
相关论文
共 50 条
  • [1] A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype
    Chida, M
    Yokoi, T
    Nemoto, N
    Inaba, M
    Kinoshita, M
    Kamataki, T
    PHARMACOGENETICS, 1999, 9 (03): : 287 - 293
  • [2] Clinical Significance of a CYP2D6 Poor Metabolizer-A Patient With Schizophrenia on Risperidone Treatment
    Bozina, Nada
    Jovanovic, Nikolina
    Lovric, Mila
    Medved, Vesna
    THERAPEUTIC DRUG MONITORING, 2008, 30 (06) : 748 - 751
  • [3] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [4] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
    Martinez de Duenas, Eduardo
    Ochoa Aranda, Enrique
    Blancas Lopez-Barajas, Isabel
    Ferrer Magdalena, Teresa
    Bandres Moya, Fernando
    Chicharro Garcia, Luis Miguel
    Gomez Capilla, Jose A.
    Zafra Ceres, Mercedes
    de Haro, Tomas
    Romero Llorens, Regina
    Ferrer Albiach, Carlos
    Ferriols Lisart, Rafael
    Chover Lara, Dolores
    Lopez Rodriguez, Angela
    Munarriz Ferrandis, Javier
    Olmos Anton, Santiago
    BREAST, 2014, 23 (04) : 400 - 406
  • [5] Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status
    Barclay, ML
    Sawyers, SM
    Begg, EJ
    Zhang, M
    Roberts, RL
    Kennedy, MA
    Elliott, JM
    PHARMACOGENETICS, 2003, 13 (10): : 627 - 632
  • [6] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [7] CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour
    Saarikoski, ST
    Sata, F
    Husgafvel-Pursiainen, K
    Rautalahti, M
    Haukka, J
    Impivaara, O
    Järvisalo, J
    Vainio, H
    Hirvonen, A
    PHARMACOGENETICS, 2000, 10 (01): : 5 - 10
  • [8] CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Trzepacz, Paula T.
    Williams, David W.
    Feldman, Peter D.
    Wrishko, Rebecca E.
    Witcher, Jennifer W.
    Buitelaar, Jan K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (02) : 79 - 86
  • [9] Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
    Dalén, P
    Dahl, ML
    Andersson, K
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (02) : 180 - 184
  • [10] Allelic diversity of the pharmacogene CYP2D6 in New Zealand Maori and Pacific peoples
    Hitchman, Leonie M.
    Faatoese, Allamanda
    Merriman, Tony R.
    Miller, Allison L.
    Liau, Yusmiati
    Graham, Oscar E. E.
    Kee, Ping Siu
    Pearson, John F.
    Fakahau, Tony
    Cameron, Vicky A.
    Kennedy, Martin A.
    Maggo, Simran D. S.
    FRONTIERS IN GENETICS, 2022, 13
12345